*** RETAINED DUPLICATE: THIS CASE WAS ALSO PREVIOUSLY REPORTED AS GENENTECH CASE = 
THIS CASE WAS RECEIVED FROM GENENTECH, INC. (US); MCN 289195 ON 2 SEPTEMBER 2009.
THIS CASE, MANUFACTURER CONTROL NUMBER 289195, IS A SPONTANEOUS REPORT FROM THE 
UNITED STATES REFERRING TO A PATIENT (AGE AND GENDER NOT REPORTED). A PHYSICIAN 
REPORTED THIS CASE. 
NO PAST MEDICAL HISTORY, CONCURRENT CONDITIONS, ALLERGIES, OR CONCOMITANT 
MEDICATIONS WERE REPORTED.
ON A DATE NOT REPORTED, THE PATIENT BEGAN THERAPY WITH RITUXAN (DOSE, ROUTE, AND 
FREQUENCY NOT REPORTED) FOR AN UNSPECIFIED INDICATION.  THE LAST DOSE OF RITUXAN 
ADMINISTERED PRIOR TO EVENT ONSET AND THE LOT NUMBER WERE NOT REPORTED. 
ON AN UNSPECIFIED DATE, IT WAS REPORTED THAT THE PATIENT EXPERIENCED SUSPECTED 
SYMPTOMS OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) (PROGRESSIVE 
MULTIFOCAL LEUCOENCEPHALOPATHY).  ASSOCIATED SYMPTOMS INCLUDED HAND TREMORS AND 
OTHER UNSPECIFIED SYMPTOMS REPORTED TO HAVE BEEN INDICATIVE OF PML. ON A DATE NOT 
REPORTED, UNSPECIFIED LABS WERE DRAWN (RESULTS NOT REPORTED) AND IT WAS REPORTED 
THAT AN INTERIM DIAGNOSIS OF CEREBRAL VASCULITIS WAS MADE AND TREATED WITH 
CYCLOPHOSPHAMIDE AND AZATHIOPRINE.  ON AN UNSPECIFIED DATE, THE PRESENCE OF JC VIRUS IN
THE PATIENT'S CSF WAS CONFIRMED. NO ADDITIONAL CLINICAL DETAILS WERE PROVIDED.  ACTION 
TAKEN WITH RITUXAN WAS NOT REPORTED.
AT THE TIME OF THE REPORT, CONFLICTING INFORMATION WAS PROVIDED REGARDING THE EVENT 
OUTCOME.  IT WAS BOTH REPORTED THAT THE PATIENT WAS IMPROVING AND THAT THE PATIENT'S 
SYMPTOMS HAD RESOLVED "AFTER BEING ON AZATHIOPRINE".
THE PHYSICIAN DID NOT PROVIDE A CAUSALITY ASSESSMENT OF THE EVENT PROGRESSIVE 
MULTIFOCAL LEUCOENCEPHALOPATHY IN RELATION TO RITUXAN. NO OTHER POSSIBLE ETIOLOGICAL 
FACTORS WERE REPORTED. 
THE EVENT WAS IDENTIFIED AS MEDICALLY SIGNIFICANT BY GENENTECH. 
ADDITIONAL INFORMATION IS BEING REQUESTED. IF RECEIVED, THE CASE WILL BE UPDATED 
Print Time: 07-JUN-2016 03:01 PM If a field is blank, there is no data for that field Page 238 of 549
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
ACCORDINGLY.
THIS CONFIRMED CASE OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) IS BEING 
EXPEDITED PER GENENTECH'S ENHANCED PV PLAN FOR PML.
Additonal information was received on 1/04/15. Following information was updated: More than 3 HCP follow up 
attempts were performed with no response. Case was considered lost to follow up.
This confirmed case of progressive multifocal leukoencephalopathy (PML) is being expedited per 
Roche/Genentech Enhanced Pharmacovigilance Plan for PML